Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. Co.'s primary product candidate, CNTY-101, is an allogeneic, chimeric antigen receptors (CAR)-induce pluripotent stem cell-derived (iPSC-derived) natural killer (iNK) cell therapy that has been engineered to express CD19 CAR, soluble IL-15, an epidermal growth factor receptor safety switch, and also contains gene edits needed to incorporate Allo-Evasion™ technology. CNTY-103 is Co.'s main product candidate targeting a solid tumor. We show 10 historical shares outstanding datapoints in our IPSC shares outstanding history coverage, used to compute IPSC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IPSC market cap history over the course of time is important for investors
interested in comparing IPSC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IPSC versus a peer is one thing; comparing
IPSC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IPSC can fluctuate over the course of history.
With this page we aim to empower investors researching IPSC by allowing them to research the IPSC market cap history. |
Free IPSC Email Alerts:
Video: The Importance of Market Cap
